PureTech Health plc (PTCHF)
PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic acetylcholine receptors for managing schizophrenia and the psychosis seen in Alzheimer's disease. Its technological foundations also encompass a regenerative biology platform applicable to conditions like androgenetic alopecia and epithelial aging, alongside an immunomodulation platform dedicated to addressing chronic and acute inflammatory disorders. Additionally, the firm develops oral therapies derived from specific bacterial consortia isolated from the human microbiome and treatments engineered to alleviate cognitive dysfunction associated with depression, multiple sclerosis, post-COVID and ICU recovery, and cancer-related conditions. Further innovations include hematopoietic stem cell-based therapies for individuals with blood cancer, a voice-activated technology platform capable of identifying health-related vocal shifts, and a proprietary system facilitating the oral delivery of biologics, vaccines, and other complex medications. In its robust development pipeline, PureTech is advancing LYT-100 for the treatment of lymphedema and other lymphatic flow anomalies, LYT-200 as an IgG4 monoclonal antibody targeting galectin-9, and LYT-210 for solid tumors. Pioneering technological frameworks under development include Glyph, a synthetic chemistry platform for lymphatic targeting; Orasome technology, which enables oral administration of large molecule therapeutic payloads; a meningeal lymphatics platform with implications for Alzheimer's and Parkinson's diseases; and the Alivio technology platform, designed for inflammation-targeted disease immunomodulation. PureTech Health plc has forged key collaboration and licensing agreements with leading pharmaceutical companies, including Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd. The company was founded in 2015 and maintains its corporate headquarters in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
PureTech Health plc
OTC:PTCHFHealthcare · Biotechnology
+7.43%$1.59
Mkt Cap$384.28M
Float241.68M
O/S241.68M
Inst Own-
SI<0.1%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$4.76M
Net Income-$112.18M
Total Assets$535.56M
Free Cash Flow-$87.03M
Debt & Equity
Debt 6%
Equity 94%
Total Debt$19.79M
Total Equity$312.57M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PTCHF's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$535.56M
Liabilities$229.4M
Accounts Receivable$8.14M
Accounts Payable$3.07M
Inventory$0
PP&E (Net)$11.52M
Goodwill$0
Intangible Assets$601K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Revenue | $4.76M | $4.32M | $750K | $2.09M | $9.98M | $8.34M | $8.69M | $16.37M | $650K | $4.43M | $11.74M | $2.01M | $7.02M | $7.93M |
| YoY Growth | 10.4% | 475.3% | -64.1% | -79.1% | 19.6% | -4.0% | -46.9% | 2418.6% | -85.3% | -62.3% | 483.5% | -71.3% | -11.5% | - |
| Cost of Revenue | $3.42M | $3.5M | $2.39M | $152.43M | $110.47M | $0 | $85.85M | $77.4M | $71.03M | $1.44M | $714K | $0 | $0 | $0 |
| Gross Profit | $1.34M | $4.32M | -$1.64M | -$150.34M | -$100.49M | $8.34M | -$77.16M | -$61.03M | -$70.39M | $2.99M | $11.03M | $2.01M | $7.02M | $7.93M |
| Gross Margin | 28.1% | 100.0% | -218.9% | -7193.4% | -1007.0% | 100.0% | -888.1% | -372.8% | -10828.5% | 67.6% | 93.9% | 100.0% | 100.0% | 100.0% |
| Research and Development | $57.83M | $54.28M | $96.23M | $116.11M | $81.52M | $61.19M | $65.17M | $57.29M | $71.67M | $41.2M | $13.41M | $2.84M | $2.83M | $4.23M |
| Selling, General, and Administrative | $20.65M | $27.49M | $49.53M | $35.67M | $30.76M | $26.5M | $34.89M | $24.43M | $46.28M | $37.16M | $18.38M | $7.17M | $3.55M | $3.77M |
| Other | $23.58M | $58.64M | $0 | $8.13M | $1.65M | $1.06M | $121K | -$278K | $14K | $46K | $448K | $0 | $0 | $0 |
| Total Operating Expenses | $102.06M | $140.41M | $146.95M | $199.9M | $160.26M | $127.87M | $144.09M | $120.39M | $116.07M | $78.36M | $55.38M | $19.46M | $10.1M | $13.98M |
| Operating Income (EBIT) | -$100.72M | -$136.09M | -$146.2M | -$197.81M | -$150.28M | -$119.53M | -$135.4M | -$104.02M | -$115.42M | -$73.93M | -$43.64M | -$17.45M | -$3.73M | -$9.38M |
| Operating Margin | -2114.7% | -3154.0% | -19493.2% | -9464.4% | -1506.0% | -1433.1% | -1558.5% | -635.4% | -17756.9% | -1668.4% | -371.7% | -867.0% | -53.2% | -118.3% |
| Interest Expense | $46.8M | $10.04M | $13.49M | $3.95M | $4.71M | $2.95M | $4.26M | $392K | $553K | $801K | $4.2M | $2.59M | $367K | $609K |
| Interest Income | $13.34M | $22.67M | $16.01M | $5.8M | $214K | $1.18M | $4.53M | $3.36M | $1.75M | $1.29M | $253K | $46K | $36K | $30K |
| Other Income (Expense) | -$12.68M | $159.87M | $110.1M | $105.02M | $91.33M | $138.5M | $613.87M | $35.58M | $44.71M | -$9.25M | -$12.68M | -$58.78M | -$1.58M | -$1.39M |
| Income Before Tax (EBT) | -$113.39M | $23.77M | -$36.1M | -$92.78M | -$58.95M | $18.97M | $478.47M | -$68.44M | -$70.71M | -$83.18M | -$56.32M | -$76.22M | -$5.31M | -$10.78M |
| Income Tax Expense | -$861K | -$4.01M | $30.52M | -$55.72M | $3.76M | $14.4M | $112.41M | $2.22M | -$14K | -$1.57M | $1.92M | -$278K | $274K | $535K |
| Net Income | -$112.18M | $53.51M | -$65.7M | -$50.35M | -$60.56M | $5.99M | $421.14M | -$43.65M | $26.47M | -$48.79M | -$39.39M | -$41.64M | -$4.3M | -$11.05M |
| Net Income Margin | -2355.4% | 1240.1% | -8759.6% | -2409.3% | -606.9% | 71.8% | 4847.4% | -266.7% | 4072.6% | -1101.2% | -335.5% | -2069.7% | -61.3% | -139.4% |
| Supplementary Data | ||||||||||||||
| EPS | -0.47 | 0.20 | -0.24 | -0.18 | -0.21 | 0.02 | 1.54 | -0.16 | 0.13 | -0.21 | -0.21 | -0.18 | -0.02 | -0.05 |
| Diluted EPS | -0.47 | 0.20 | -0.24 | -0.18 | -0.21 | 0.02 | 1.50 | -0.16 | 0.13 | -0.21 | -0.21 | -0.18 | -0.02 | -0.05 |
| Weighted Average OS | 240.79M | 269.66M | 276.30M | 284.76M | 286.59M | 285.60M | 283.43M | 273.85M | 235.53M | 229.51M | 185.28M | 227.25M | 227.25M | 227.25M |
| EBITDA | -$97.29M | $37.38M | -$12.03M | -$51.08M | -$46.95M | $28.56M | $487.78M | -$65.27M | -$67.91M | -$81.17M | -$49.42M | -$69.35M | -$4.76M | -$9.67M |
| EBITDA Margin | -2042.9% | 866.3% | -1603.5% | -2443.9% | -470.5% | 342.4% | 5614.4% | -398.7% | -10447.4% | -1831.9% | -421.0% | -3446.9% | -67.8% | -121.9% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Assets | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash and Cash Equivalents | $254.47M | $280.64M | $191.08M | $149.87M | $465.71M | $403.88M | $132.36M | $117.05M | $72.65M | $62.96M | $134.75M | $218.96M | $7.17M | $10.86M |
| Short-Term Investments | $24.87M | $86.67M | $136.06M | $200.23M | $0 | $0 | $30.09M | $133.83M | $117.03M | $219.41M | $179.78M | $1.17M | $1.83M | $1.18M |
| Cash and Short-Term Investments | $279.34M | $367.31M | $327.14M | $350.1M | $465.71M | $403.88M | $162.45M | $250.88M | $189.67M | $282.37M | $314.53M | $220.13M | $9M | $12.03M |
| Accounts Receivable | $8.14M | $12.9M | $2.38M | $12.32M | $3.17M | $2.94M | $0 | $1.33M | $1.8M | $125K | $636K | $1.75M | $2.67M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $28.01M | $0 | $2.12M | $2.2M | $0 | $0 | $0 | -$472K | -$122K | $0 |
| Other Current Assets | $11.44M | $1.64M | $13.37M | $12.16M | $18.59M | $2.12M | $2.12M | $2.2M | $927K | $897K | $896K | $0 | $123K | $0 |
| Total Current Assets | $305.51M | $386.26M | $347.2M | $386.19M | $501.81M | $414.35M | $168.84M | $259.79M | $198.11M | $288.15M | $318.2M | $223.72M | $12.14M | $13.54M |
| Long-Term Assets | ||||||||||||||
| Property, Plant & Equipment Net | $11.52M | $15.13M | $19.36M | $37.24M | $43.94M | $42.87M | $43.84M | $8.32M | $6.86M | $6.92M | $4.52M | $1.23M | $1.21M | $1.08M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $601K | $601K | $906K | $831K | $987K | $899K | $625K | $3.08M | $3.31M | $3.52M | $3.87M | $3M | $3.16M | $3.34M |
| Long-Term Investments | $217.77M | $107.16M | $184.96M | $60.81M | $397.68M | $531.86M | $695.46M | $35.93M | $14.33M | -$219.32M | -$179.68M | -$1.09M | -$1.58M | $40K |
| Deferred Tax Assets | $0 | -$107.16M | $0 | $217.56M | -$397.68M | -$531.86M | $142K | $449K | $142K | $219.41M | $179.78M | $1.17M | $1.83M | $1.18M |
| Other Long-Term Assets | $166K | $93.49M | $141.54M | $10K | $399.27M | $531.87M | $32.27M | $134.2M | $117.1M | $65K | $57K | $5K | $3K | $9K |
| Total Long-Term Assets | $230.06M | $216.38M | $346.77M | $316.45M | $444.2M | $575.64M | $772.33M | $181.98M | $141.74M | $10.6M | $8.55M | $4.31M | $4.63M | $5.64M |
| Other Assets | $0 | $0 | $0 | $1K | $0 | $1K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $535.56M | $602.63M | $693.97M | $702.65M | $946.01M | $989.99M | $941.18M | $441.76M | $339.85M | $298.75M | $326.75M | $228.03M | $16.77M | $19.18M |
| Liabilities | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Accounts Payable | $3.07M | $5.52M | $14.64M | $26.5M | $11.35M | $8.87M | $11.1M | $4.64M | $3.39M | $2.08M | $2.39M | $1.61M | $905K | $1.19M |
| Short-Term Debt | $4.92M | $4.11M | $3.7M | $7.5M | $5.5M | $26.45M | $1.46M | $12.01M | $7.46M | $6.95M | $4.96M | $6.95M | $4.26M | $1.46M |
| Current Income Tax Payable | $0 | $75K | $0 | $57K | $57K | $1.26M | $93K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | -$29.46M | $30.57M | $31.32M | $22.63M | $22.21M | $30.8M | $129.01M | $88.38M | $87.05M | $70.21M | $7.45M | $10.91M |
| Other Current Liabilities | $31.77M | $27.18M | $173K | $31.59M | $183.33M | $132.75M | $92.45M | $207.08M | $121.04M | $97.62M | $61.29M | $11.78M | $9.14M | $7.87M |
| Total Current Liabilities | $46.38M | $41.39M | $51.37M | $96.89M | $226.13M | $180.92M | $139.2M | $265.76M | $273.86M | $204.08M | $160.52M | $93.67M | $22.76M | $21.43M |
| Long-Term Liabilities | ||||||||||||||
| Long-Term Debt | $0 | $0 | $0 | $10.24M | $14.26M | $14.82M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $4.13M | $2.66M | $0 | $1.22M | $1.37M | $159K | $203K | $291K | $561K | $1.53M | $1.06M |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $19.64M | $89.77M | $108.63M | $115.44M | $6.43M | $4.4M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $171.91M | $138.64M | $166.12M | $19.65M | $92.42M | $108.63M | $0 | $8.67M | $1.58M | $2.26M | $1.89M | $668K | $501K | $48K |
| Total Long-Term Liabilities | $183.02M | $153.31M | $184.37M | $58.17M | $135.72M | $155.53M | $151.58M | $9.03M | $1.99M | $2.26M | $2.18M | $668K | $2.03M | $1.11M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $229.4M | $194.7M | $235.74M | $155.06M | $361.86M | $336.45M | $290.78M | $274.79M | $275.85M | $206.34M | $162.7M | $94.34M | $24.79M | $22.54M |
| Stockholders' Equity | ||||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $4.87M | $4.86M | $5.46M | $5.46M | $5.44M | $5.42M | $5.41M | $5.38M | $4.68M | $4.61M | $4.52M | $159.36M | $1.27M | $1.27M |
| Retained Earnings | $61.37M | $32.49M | $83.82M | $149.52M | $199.87M | $260.43M | $254.44M | -$167.69M | -$127.87M | -$160.34M | -$111.42M | -$70.42M | -$35.06M | -$30.9M |
| Comprehensive Income & Other | $182K | -$4.54M | $129.15M | -$14.47M | -$39.53M | -$23.58M | -$18.28M | $20.93M | $34.58M | $13.23M | $12.77M | $90.06M | $32.91M | $0 |
| Other Stockholders' Equity | $246.33M | $377.36M | $374.79M | $387.25M | $388.2M | $403.9M | $408.19M | $437.82M | $337.5M | $333.39M | $333.02M | $90.06M | $32.91M | $32.72M |
| Total Equity | $312.57M | $414.71M | $464.07M | $542.22M | $593.51M | $669.75M | $668.04M | $275.51M | $214.3M | $177.67M | $226.12M | $179M | -$884K | $3.09M |
| Minority Interest | -$6.41M | -$6.77M | -$5.83M | $5.37M | -$9.37M | -$16.21M | -$17.64M | -$108.53M | -$150.31M | -$85.25M | -$62.07M | -$45.32M | -$7.14M | -$6.45M |
| Total Liabilities and Equity | $541.97M | $609.41M | $699.81M | $697.28M | $955.37M | $1.01B | $958.82M | $550.3M | $490.15M | $384M | $388.82M | $273.35M | $23.91M | $25.63M |
| Supplementary Data | ||||||||||||||
| Total Debt | $19.79M | $22.36M | $25.34M | $46.87M | $52.02M | $76.62M | $39.3M | $12.37M | $7.46M | $6.95M | $4.96M | $6.95M | $4.26M | $1.46M |
| Net Debt | -$234.68M | -$258.28M | -$165.74M | -$102.99M | -$413.68M | -$327.26M | -$93.06M | -$104.68M | -$65.19M | -$56.01M | -$129.8M | -$212.01M | -$2.91M | -$9.4M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Operating Activities | ||||||||||||||
| Net Income | -$110.08M | $27.78M | -$67.28M | -$37.06M | -$62.71M | $4.57M | $366.06M | -$70.66M | -$70.7M | -$81.61M | -$58.24M | -$75.94M | -$5.16M | -$12.25M |
| Depreciation & Amortization | $3.42M | $3.57M | $4.93M | $8.89M | $7.29M | $6.64M | $6.67M | $2.78M | $2.1M | $1.57M | $740K | $455K | $453K | $500K |
| Deferred Income Tax | $0 | $0 | $0 | -$179.39M | -$112.61M | -$151.35M | -$546.61M | -$19.42M | -$116.81M | -$783K | -$383K | $233K | $1.36M | $3.25M |
| Stock-Based Compensation | $8.22M | $22.85M | $4.42M | $14.7M | $13.95M | $10.72M | $14.47M | $12.64M | $11.85M | $10.15M | $11.1M | $2.81M | $290K | $408K |
| Changes in Working Capital: | ||||||||||||||
| Accounts Receivable | -$241K | $629K | $9.75M | -$7.59M | -$606K | -$564K | $776K | $446K | -$1.76M | $532K | $1.07M | $794K | -$2.33M | $0 |
| Inventory | $0 | $0 | $0 | $289K | -$87K | $562K | -$577K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.05M | $0 | $0 | $21.63M | $8.2M | $645K | $11.59M | $4.87M | $5.5M | $3.23M | $4.17M | $0 | $0 | $0 |
| Other Working Capital | -$1.9M | -$10.87M | $7.77M | $1.59M | -$6.64M | -$9.17M | $3.23M | $4.21M | -$626K | -$1.99M | -$260K | -$1.38M | $1.24M | $0 |
| Total Working Capital Change | -$3.19M | -$10.24M | $17.52M | $15.92M | $861K | -$8.53M | $15.03M | $9.96M | $2.97M | $1.94M | $4.81M | $2.87M | -$5.96M | $5.13M |
| Other Non-Cash Items | $14.61M | -$178.34M | -$65.5M | -$1.85M | -$5.05M | $6.11M | $46.23M | -$8.1M | $81.9M | $10.7M | $12.99M | $59.26M | $1.61M | $4.76M |
| Net Cash from Operating | -$87.02M | -$134.37M | -$105.92M | -$178.79M | -$158.27M | -$131.83M | -$98.16M | -$72.8M | -$88.69M | -$58.03M | -$28.61M | -$10.54M | -$8.77M | -$1.45M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | -$6K | -$11K | -$70K | -$2.18M | -$5.66M | -$5.42M | -$12.54M | -$4.49M | -$2.17M | -$3.68M | -$4.61M | -$420K | -$588K | -$1.45M |
| Acquisitions | $275K | -$105.97M | -$13.23M | -$20.44M | $321K | -$10M | -$16.04M | -$13.39M | -$16.34M | $0 | $0 | $0 | $79K | $0 |
| Purchases of Investments | -$86.98M | -$309.6M | -$200.43M | -$268.73M | -$500K | -$1.15M | -$91.25M | -$169.95M | -$147.2M | -$312.82M | -$385.38M | -$2.22M | -$3.49M | -$2.52M |
| Sales of Investments | $151.36M | $656.22M | $277.87M | $183.71M | $218.13M | $380.7M | $183.29M | $148.06M | $249.4M | $273.27M | $205.75M | $3.39M | $3.08M | $3.77M |
| Other Investing Activities | $50K | $255K | $4.85M | $416K | -$14.91M | $350K | $191K | $125K | -$80K | -$39.55M | -$1.16M | -$53K | $54K | -$617K |
| Net Cash from Investing | $64.7M | $240.89M | $68.99M | -$107.22M | $197.38M | $364.48M | $63.66M | -$39.65M | $83.68M | -$43.23M | -$184.24M | $747K | -$858K | -$200K |
| Financing Activities | ||||||||||||||
| Debt Repaid | - | - | - | -$393K | -$2.21M | -$11.88M | -$1.43M | -$5.96M | -$2.45M | -$2.06M | -$1.48M | -$7.59M | -$1.78M | $2.05M |
| Common Stock Issuance | $108K | $895K | $1.15M | $332K | $0 | -$11.76M | $0 | $152.03M | $12.4M | $27.26M | $235.66M | $55.84M | $0 | $698K |
| Common Stock Repurchases | -$2.1M | -$107.56M | -$19.65M | -$26.49M | -$13.33M | $0 | -$1.28M | -$35K | -$66K | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | -$112K | $0 | -$91K | -$100K | $0 | -$96K | -$2K | -$136K |
| Other Financing Activities | -$4.48M | $89.71M | $97.79M | -$4.54M | $33.84M | $25M | -$1.79M | -$1.07M | $0 | -$100K | $48.8M | -$174K | $4.11M | $2.74M |
| Net Cash from Financing | -$6.47M | -$16.96M | $78.14M | -$29.83M | $22.73M | $38.87M | $49.91M | $156.89M | $14.7M | $29.49M | $285.94M | $64.72M | $5.94M | $1.26M |
| Forex Effect | $1.28M | $0 | $0 | $0 | -$1K | $1K | -$104K | -$44K | -$3K | -$16K | -$294K | -$138K | $9K | -$7K |
| Net Change in Cash | -$27.52M | $89.56M | $41.22M | -$315.84M | $61.83M | $271.52M | $15.31M | $44.4M | $9.69M | -$71.79M | $72.79M | $54.79M | -$3.68M | -$403K |
| Supplementary Data | ||||||||||||||
| Operating Cash Flow | -$87.02M | -$134.37M | -$105.92M | -$178.79M | -$158.27M | -$131.83M | -$98.16M | -$72.8M | -$88.69M | -$58.03M | -$28.61M | -$10.54M | -$8.77M | -$1.45M |
| Capital Expenditure | -$6K | -$11K | -$245K | -$2.18M | -$5.66M | -$5.42M | -$12.54M | -$4.49M | -$2.17M | -$3.68M | -$4.61M | -$420K | -$588K | -$1.45M |
| Free Cash Flow | -$87.03M | -$134.38M | -$106.16M | -$180.97M | -$163.94M | -$137.25M | -$110.69M | -$77.29M | -$90.86M | -$61.71M | -$33.22M | -$10.96M | -$9.36M | -$2.9M |
| Cash at Beginning | $281.99M | $191.08M | $149.87M | $465.71M | $403.88M | $132.36M | $117.05M | $72.65M | $62.96M | $134.75M | $61.96M | $7.17M | $10.86M | $11.26M |
| Cash at End | $254.47M | $280.64M | $191.08M | $149.87M | $465.71M | $403.88M | $132.36M | $117.05M | $72.65M | $62.96M | $134.75M | $61.96M | $7.17M | $10.86M |